Advisory Board
The 4D Biomedical Advisory Board meets quarterly with the Consulting Team to review:
- The sector, trends and latest deals
- Progress on projects
Individual board members are available to be engaged on specific projects as agreed with clients.
The Board holds an annual biomedical dinner with guest speaker.
Advisory Board Members
Dr Andy Richards
Andy Richards is a well known biotechnology entrepreneur and business angel. He is currently a director of Vectura Group plc, Biowisdom Ltd, Daniolabs Ltd, Theradeas Ltd, Cancer Research Technology Ltd (the commercial arm of CR-UK), Babraham Bioscience Technology Ltd, Babraham Bioconcepts Ltd and non-executive Chairman of Geneservice Ltd, Altacor Ltd and Pharmakodex Ltd.
His early career was with ICI (now AstraZeneca) and PA Technology. He was a founder of Chiroscience in 1992 and an executive director through to its merger with Celltech in August 1999. He also founded and invested in Arakis, Cambridge Biotechnology Ltd, Amedis Pharmaceuticals and Sirus Pharmaceuticals.
Andy is a founder member of the Cambridge Angels, a founder investor in Library House, a member of the Council of UEA, a director of the Bioindustry Association (BIA) and an advisor to Toscana Life Sciences. He was Cambridge Evening News Businessman of the Year in 2005.
Peter Keen
Peter Keen is Corporate Development and Finance Director of Serentis Inc. He was formerly CFO of Arakis Ltd where he led the successful £106m trade sale; co-founder of Merlin Ventures and MD until 2003; and FD of Chiroscience plc where he oversaw the LSE listing.
Peter is Chairman, Non-Executive Director and adviser to a number of leading UK companies and funds, including Ark Therapeutics Group plc, Abcam plc, the Biotech Growth Trust plc and venture capital company DFJ Esprit.
Dr Ann Hayes
Ann Hayes worked for 22 years for GlaxoWellcome as a Director in Drug Discovery, with particular expertise in the areas of CNS and pain. Ann left GSK in 2001 and has co-founded three companies, Ionix Pharmaceuticals (which has been bought by Vernalis), Therasci (which has been bought by CeNeS), and Theradeas.
Ann is a Non-Executive Director for Curidium Ltd and Plethora Solutions plc, and a member of the advisory boards for Lectus Therapeutics, CeNeS, Paradigm, Ingenium and Neurosolutions. She has also held Non-Executive Director positions at Therasci, Ionix and Sirus (which was sold to Arakis). She consults for CeNes and Shire, as well as doing ad hoc consulting for a number of small companies and VCs. She lectures on the Masters in Bioscience Enterprise at Cambridge University.
Dr David Cotterell
David Cotterell is founder and MD of Apex Healthcare, the specialist pharmaceutical market research and product consulting house. He was at GlaxoSmithKline Beecham from 1990-1996. He holds a PhD and MBA.
Simon Cartmell
Simon Cartmell is CEO of Apatech Ltd, a world leader in synthetic bone graft technologies. Previously he worked 17 years at GlaxoWellcome in a number of U.K. and global roles, including Therapy Area Director, Infectious Diseases and Hepatitis.
Simon joined Vernalis plc (formerly Vanguard Medica plc) as COO in 1998 overseeing its acquisition of Cerebrus plc in 1999. He joined the main board of Celltech plc in the role of CEO for Celltech Pharmaceuticals in mid 2000. More recently Simon has been interim CEO of Entomed sa, where he remains a Non-Executive Director. He is also Non-Executive Chairman of Curidium Ltd, an advisor to a number of Venture and Private Equity groups and a Sloan Fellow from London Business School.
Martin Wehling
Formerly Director of Discovery Medicine at Astra Zeneca’s cardiovascular site in Mölndal, Professor Wehling is full Professor of clinical pharmacology at the University of Heidelberg. He has longstanding experiences in translating basic science into human studies. His specialist field is in bridging gaps between preclinical and clinical development, assembling, developing and profiling of biomarkers with particular assessment of their predictive value and translational medicine planning from early discovery/human stages to clinical trials, smart early human trial design and developmental decision trees (stop/go algorithms).
Professor Wehling has authored >200 scientific publications and several books, received prestigious awards (e.g. Heisenberg scholarship by Deutsche Forschungsgemeinschaft) and his scientific contributions to the identification and analysis of nongenomic steroid actions coined a novel science segment. He is also an experienced clinician with experiences in invasive cardiology (appr. 4000 cardiac catheters and interventions) and runs an outpatient clinic for geriatric pharmacotherapy.
Bryan Morton
Bryan Morton has a BSc in Pharmacology from Aberdeen University and an MBA from Durham University. He began his pharmaceutical career in sales and has held positions of increasing responsibility in medical information, marketing, sales management, business development and general management during a 30 year career in the healthcare industry, largely with Merck and Co. Inc. and Bristol Myers Squibb.
During this time he has lived and worked in the UK, USA, Australia and Belgium and in 2003 he founded Zeneus Pharma through the acquisition of Elan’s European sales and marketing business for $120m in a private equity deal.
Following the sale of Zeneus Pharma for $360m in late 2005, Bryan founded EUSA Pharma in 2006 with backing from Essex Woodlands Health Ventures.
Simon Kerr
Director, Biosciences Ventures at Imperial Innovations. Having worked initially in marketing and business development roles in Beecham Pharmaceuticals and Wellcome plc, Simon moved into the biotechnology sector during the mid-90s. He has extensive experience of emerging bioscience businesses, has held board-level positions in four unlisted companies and has led over 25 licensing, financing and M&A transactions. He was most recently Commercial Director of CeNeS plc until its acquisition by Paion AG in June 2008. Simon has a BA Economics from the University of Exeter and an MSc from London Business School.